Trial Profile

A Phase 1/2, First-in-human Study of the Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of TT-816 as Monotherapy or in Combination With a PD-1 Inhibitor in Patients With Advanced Cancers (SEABEAM) (MK3475-E88)

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 25 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; TT-816 (Primary)
Indications Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms SEABEAM
Sponsors Teon Therapeutics

26 Oct 2023 Status changed from active, no longer recruiting to discontinued.
22 Aug 2023 Status changed from recruiting to active, no longer recruiting.
18 Jan 2023 According to a Teon Therapeutics media release, the company has entered into the clinical trial collaboration agreement with Merck for this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com